---
schema_version: "secwatch.filing_event.v1"
accession: "0001396814-22-000057"
form_type: "8-K"
ticker: "PCRX"
cik: "0001396814"
company_name: "Pacira BioSciences, Inc."
filed_at: "2022-09-13T23:59:59+00:00"
generated_at: "2026-06-23T09:58:39.366463+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Pacira reports preliminary August net product sales of $59.1M; EXPAREL up 13% YoY

## Summary
- Total net product sales of $59.1M for August 2022; EXPAREL $46.7M (vs $41.4M in Aug 2021).
- EXPAREL average daily sales were 108% of Aug 2021; 23 selling days vs 22.
- ZILRETTA contributed $9.7M; iovera° $1.5M (up from $0.9M); veterinary sales $1.2M.
- More than 11 million patients have received EXPAREL since launch.
- Company not providing 2022 revenue guidance due to COVID-19 and labor uncertainty.

## SEC filing metadata
- accession: 0001396814-22-000057
- form_type: 8-K
- ticker: PCRX
- cik: 0001396814
- company_name: Pacira BioSciences, Inc.
- filed_at: 2022-09-13T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1396814/000139681422000057/0001396814-22-000057-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1396814/000139681422000057/pcrx-20220913.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001396814-22-000057
- JSON: https://secwatch.observer/filing/0001396814-22-000057.json
- Plain text: https://secwatch.observer/filing/0001396814-22-000057.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.